Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

IPSC

Strong SellSinker

Century Therapeutics, Inc. · Healthcare · United States · $367M · Avg Vol: $901K/d

17
StockRank
Get insider-trade alerts
Q
25
V
32
M
42
P/E (TTM)
—
ROE
-49.7%
D/E
0.2x
Dividend %
—
Dir. Trades · 180d
−$13.3K →
Buybacks · 180d
None →

COMPANY DESCRIPTION

Century Therapeutics, Inc. is a biotechnology company focused on developing allogeneic induced pluripotent stem cell (iPSC)-derived cell therapies for various cancers. Leveraging its proprietary iPSC platform, the company aims to create off-the-shelf, gene-edited cell therapies that can be administered to a broad patient population. This innovative approach positions Century as a key player in the emerging field of iPSC-based oncology treatments.

FINANCIAL SUMMARY (USD)

Year2022202320242025CAGRTTM
Revenue5.2M2.2M6.6M109.2M175.9%—
EPS-0.74-0.77-0.77-0.07—-0.93
Shares180.4M180.4M180.4M180.4M0.0%181.1M
Debt49.4M48.2M53.8M43.6M-4.1%38.7M
Equity302.7M184.8M161.4M158.9M-19.3%—
Op CF14.1M-88.3M-110.1M-103.9M—-86.8M
Inv CF-13.1M61.1M47.5M107.5M——
Fin CF27.2M-9.7M74.6M0.2M——
Loading 1Y...
PRICE (1Y)-11.4%
1.901.982.062.152.23Jul 30Aug 20Sep 10
SMA 50SMA 200

Close
$1.94
RSI (14)
45.1
52W High
$3.04
From 52W High
0.6%

SCORE BREAKDOWN

Quality
25
ROIC
-53.3%14.8
ROE
-49.7%18.5
GP/Assets
-35.3%2.2
Op. Margin
0.0%38.1
FCF/Assets
-46.8%7.3
Piotroski
438.9
Int. Cover
—N/A
D/E Ratio
0.17x53.7
Current Ratio
8.28x84.2
Value
32
P/E (TTM)
—N/A
EV/EBITDA
-3.1x25.0
P/FCF
—N/A
P/B
1.6x70.1
P/S
—N/A
Div Yield
—N/A
Momentum
42
52W High %
64%41.6
RS 6M
-42%18.5
SMA 50/200
1.07x71.2
EPS Rev 4W
+1.1%48.6
EPS Rev 12W
+1.1%62.3
EPS Improve
+51%55.5
Q Growth
—N/A

FUNDAMENTALS

Market Cap
$367M
P/E (Forward)
-4.7x
Gross Margin
—

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of IPSC are excluded.

TickerCompanyMkt CapStockRankSignal
IPSCCentury Therapeutics, Inc.(you)$367M17Strong Sell
ZNTLZentalis Pharmaceuticals, Inc.$360M17Strong Sell
DMACDiaMedica Therapeutics Inc.$345M16Strong Sell
VNDAVanda Pharmaceuticals Inc.$320M18Strong Sell
AVIRAtea Pharmaceuticals, Inc.$430M17Strong Sell
LRMRLarimar Therapeutics, Inc.$417M16Strong Sell
FULCFulcrum Therapeutics, Inc.$294M17Strong Sell
IMRXImmuneering Corporation$323M19Strong Sell
OBIOOrchestra BioMed Holdings, Inc.$312M19Strong Sell
ENTAEnanta Pharmaceuticals, Inc.$396M13Strong Sell

Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%

Century Therapeutics, Inc. (IPSC): Stock Score Summary

Century Therapeutics, Inc. (IPSC) has a MoatMap StockRank of 17/100 based on Quality (25/100), Value (32/100), and Momentum (42/100) factor scores. The current signal is STRONG SELL.

Century Therapeutics, Inc. is a biotechnology company focused on developing allogeneic induced pluripotent stem cell (iPSC)-derived cell therapies for various cancers. Leveraging its proprietary iPSC platform, the company aims to create off-the-shelf, gene-edited cell therapies that can be administered to a broad patient population. This innovative approach positions Century as a key player in the emerging field of iPSC-based oncology treatments.

Key Financial Metrics

Price$1.94
Market Cap$367M
P/E (Forward)-4.66
Price/Book1.64
Return on Equity-49.7%
Return on Invested Capital-53.3%
Debt/Equity0.17x
Operating Margin0.0%
Free Cash Flow$-105M

Century Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Century Therapeutics, Inc.’s (IPSC) StockRank?
MoatMap’s StockRank for Century Therapeutics, Inc. (IPSC) is 17/100, with a Strong Sell signal. It is a composite of Quality (25), Value (32), and Momentum (42) factor ranks across MoatMap’s universe of 25,000+ stocks.
Does Century Therapeutics, Inc. have an economic moat?
Century Therapeutics, Inc. (IPSC) has a Quality factor score of 25/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Century Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Century Therapeutics, Inc. (IPSC) is Strong Sell, based on a StockRank of 17/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Century Therapeutics, Inc. in?
Century Therapeutics, Inc. (IPSC) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksIPSC deep dive reportAI ChampionsHow we score stocksSense-check another stock